Comparing the current results to its competitors, Morphic Holding Inc reported Revenue decrease in the 2 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.8 %, recorded in the same quarter.
Morphic Holding inc , slower than the average decrease reported by the company's competitors of -58.73 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -58.73 %
Morphic Holding Inc 's Comment on Competition and Industry Peers
The company is developing MORF-057, an oral small molecule α4β7-specific integrin inhibitor intended for the treatment of inflammatory bowel disease (IBD). Currently approved IBD therapies include Entyvio (vedolizumab), an injectable α4β7 monoclonal antibody marketed by Takeda Pharmaceutical Company Limited. The biotechnology and pharmaceutical industries are marked by rapid technological change, intense competition, and strong intellectual property protection. The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Despite significant investment, no oral integrin therapies have been approved in the United States or Europe, posing a competitive challenge. Key factors in competition include product efficacy, safety, and convenience.
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the discovery and development of innovative medicines. Their business model centers around leveraging a decentralized approach, with multiple subsidiary companies working autonomously to accelerate the research and development of potential therapeutics across various disease areas. By bringing together diverse expertise and resources, Centessa aims to efficiently advance breakthrough therapies and deliver impactful solutions to patients in need.
Corcept Therapeutics Inc operates using a business model that focuses primarily on the research, development, and commercialization of pharmaceutical products. The company aims to discover and develop medications for conditions related to cortisol dysregulation, with a specific focus on Cushing's syndrome and psychiatric disorders. Additionally, Corcept Therapeutics Inc aims to ensure the successful commercialization of their products through collaborations and partnerships with other organizations to reach a wider market.
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
Sources:
Morphic Holding inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Morphic Holding inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
